Skip to content

Study · In vitro (cells) · 2004

4 results

[The effect of ladasten on the activation-induced expression of Fas receptor on T-lymphocytes and their sensitivity to Fas-induced apoptosis].

Vakhitova IuV, Salimgareeva MKh, Sibiriak SV, Kurchatova NN, Seredin SB

Eksperimental'naia i klinicheskaia farmakologiia1 Sept 2004

PMID15559634 (opens in a new tab)PepBankPUB-15559634
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Mechanism

    In human T-lymphocytes, ladasten enhanced TCR-mediated mitogenic stimulation.

    In plain wordsIn cells, ladasten enhanced stimulation of human T-lymphocyte multiplication.

    Peptide
    Bromantane
    Outcome
    IncreaseTCR-mediated proliferation
    Study

    humann: not reported in source

    peripheral blood T-lymphocytes
    Outcome group
    Cell viability and death · Immune and inflammation
    Studied dose
    0.1-10 microMAs given in this study (human).

    Source sentences

    Summary
    In the range of concentrations 0.1-10 microM, ladasten exhibited a comitogenic effect on the TCR-mediated stimulation of T-lymhocytes ion the peripheral human blood, which was accompanied by an increase in the level of phosphorylated form of ERK-2.
  2. 02LabIn vitro (cells)Mechanism

    In human T-lymphocytes, ladasten increased phosphorylated ERK-2 levels.

    In plain wordsIn cells, ladasten increased phosphorylated ERK-2 levels in human T-lymphocytes.

    Peptide
    Bromantane
    Outcome
    IncreasePhosphorylated ERK-2
    Study

    humann: not reported in source

    peripheral blood T-lymphocytes
    Outcome group
    Cell viability and death · Immune and inflammation
    Studied dose
    0.1-10 microMAs given in this study (human).

    Source sentences

    Summary
    In the range of concentrations 0.1-10 microM, ladasten exhibited a comitogenic effect on the TCR-mediated stimulation of T-lymhocytes ion the peripheral human blood, which was accompanied by an increase in the level of phosphorylated form of ERK-2.
  3. 03LabIn vitro (cells)Mechanism

    In T-lymphocytes, ladasten virtually did not change activation-induced Fas receptor expression.

    In plain wordsIn cells, ladasten virtually did not change activation-induced Fas receptor expression.

    Peptide
    Bromantane
    Outcome
    No significant changeFas receptor expression
    Study

    humann: not reported in source

    peripheral blood T-lymphocytes
    Outcome group
    Cell viability and death · Immune and inflammation
    Studied dose
    0.1-10 microMAs given in this study (human).

    Source sentences

    Summary
    At the same time, ladasten virtually did not change the activation-induced expression of Fas-receptor on T-lymphocytes, but reduced the rate of the Fas-induced apoptosis.
  4. 04LabIn vitro (cells)Mechanism

    In T-lymphocytes, ladasten reduced the rate of Fas-induced apoptosis.

    In plain wordsIn cells, ladasten reduced Fas-induced death of T-lymphocytes.

    Peptide
    Bromantane
    Outcome
    DecreaseFas-induced apoptosis
    Study

    humann: not reported in source

    peripheral blood T-lymphocytes
    Outcome group
    Cell viability and death · Immune and inflammation
    Studied dose
    0.1-10 microMAs given in this study (human).

    Source sentences

    Summary
    At the same time, ladasten virtually did not change the activation-induced expression of Fas-receptor on T-lymphocytes, but reduced the rate of the Fas-induced apoptosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.